Localization of Tissue Inhibitor of Matrix Metalloproteinases in Alzheimer's Disease and Normal Brain

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Neuropathology and Experimental Neurology

• Publication date

  1995-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/00005072-199501000-00002PMID 7815076
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metalloproteinase-dependent neurite outgrowth within a synthetic extracellular matrix is induced by nerve growth factor.

  1994cited by this paper
• Gelatinase A not alpha-secretase?

  1994cited by this paper
• Secretion of beta-amyloid precursor protein involves multiple cleavage sites.

  1994cited by this paper
• Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase.

  1994cited by this paper
• Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions.

  1993cited by this paper
• Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors.

  1993cited by this paper
• Processing of the beta-amyloid precursor. Multiple proteases generate and degrade potentially amyloidogenic fragments.

  1993cited by this paper
• Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament.

  1993cited by this paper
• Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells.

  1993cited by this paper
• alpha 2-Macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease.

  1993cited by this paper
• Making the diagnosis of Alzheimer's disease. A primer for practicing pathologists.

  1993cited by this paper
• Aluminum-induced nonenzymatic phospho-incorporation into human tau and other proteins.

  1993cited by this paper
• A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor

  1993cited by this paper
• Cancer cell invasion and metastasis.

  1992cited by this paper
• Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments

  1992cited by this paper
• Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids

  1992cited by this paper
• Amyloid beta-peptide is produced by cultured cells during normal metabolism.

  1992cited by this paper
• Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma.

  1992cited by this paper
• Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin.

  1992cited by this paper
• Comparison of extracellular matrix-degrading activities between 64-kDa and 90-kDa gelatinases purified in inhibitor-free forms from human schwannoma cells.

  1992cited by this paper
• Processing of the amyloid protein precursor to potentially amyloidogenic derivatives.

  1992cited by this paper
• Production of the Alzheimer amyloid beta protein by normal proteolytic processing.

  1992cited by this paper
• Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor.

  1992cited by this paper
• Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease.

  1991cited by this paper
• Demonstration of an active component of inter-alpha-trypsin inhibitor in the brains of Alzheimer type dementia.

  1991cited by this paper
• Alzheimer patients: preamyloid deposits are immunoreactive with antibodies to extracellular domains of the amyloid precursor protein.

  1991cited by this paper
• Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.

  1990cited by this paper
• Cleavage of amyloid beta peptide during constitutive processing of its precursor.

  1990cited by this paper
• Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells.

  1990cited by this paper
• Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells.

  1990cited by this paper
• Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing.

  1990cited by this paper
• Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor.

  1989cited by this paper
• Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein.

  1989cited by this paper
• Protease nexin I immunostaining in alzheimer's disease

  1989cited by this paper
• Alzheimer's disease amyloid precursor protein is present in senile plaques and cerebrospinal fluid: immunohistochemical and biochemical characterization.

  1989cited by this paper
• Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease.

  1988cited by this paper
• Microwave fixation provides excellent preservation of tissue, cells and antigens for light and electron microscopy

  1988cited by this paper
• Rapid microwave fixation of human tissues for light microscopic immunoperoxidase identification of diagnostically useful antigens.

  1987cited by this paper
• A COMPARATIVE STUDY OF MODIFIED BIELSCHOWSKY, BODIAN AND THIOFLAVIN S STAINS ON ALZHEIMER'S NEUROFIBRILLARY TANGLES

  1986cited by this paper
• Selective extraction of small and large molecules from the cerebrospinal fluid by Purkinje neurons.

  1985cited by this paper
• Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro.

  1983cited by this paper

• Neutrophils and NETosis in Alzheimer's disease: Unraveling pathogenic mechanisms and novel therapeutic targets.

  2025cites this paper
• The Link Between Matrix Metalloproteinases and Alzheimer’s Disease Pathophysiology

  2024cites this paper
• Sex-specific associations of matrix metalloproteinases in Alzheimer’s disease

  2023cites this paper
• Molecular characterization of matrix metalloproteinase gene family across primates

  2022cites this paper
• Relationship between Cerebrospinal Fluid Matrix Metalloproteinases Levels and Brain Amyloid Deposition in Mild Cognitive Impairment

  2021cites this paper
• Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives

  2021cites this paper
• The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases

  2020cites this paper
• Mesenchymal stem cells modulate misfolded α-synuclein in parkinsonian disorders: A multitarget disease-modifying strategy.

  2020cites this paper
• The past, present and future perspectives of matrix metalloproteinase inhibitors.

  2019cites this paper
• In silico screening of anticholinesterase alkaloids for cyclooxygenase-2 (COX-2) and matrix metalloproteinase 8 (MMP-8) inhibitory potentials as multi-target inhibitors of Alzheimer’s disease

  2019cites this paper
• Metalloproteinases and their tissue inhibitors in Alzheimer’s disease and other neurodegenerative disorders

  2019cites this paper
• Imbalances in tissue inhibitors of metalloproteinases differentiate choroidal neovascularization from geographic atrophy

  2018cites this paper
• The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders

  2018cites this paper
• NETosis in Alzheimer’s Disease

  2017cites this paper
• Tenascin-C Is Associated with Cored Amyloid-&bgr; Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly

  2016cites this paper
• Fragment‐Based Discovery of 5‐Arylisatin‐Based Inhibitors of Matrix Metalloproteinases 2 and 13

  2016cites this paper
• Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies

  2016cites this paper
• Region‐Specific Alterations of Matrix Metalloproteinase Activity in Multiple System Atrophy

  2015cites this paper
• MOLECULAR DOCKING AND 3D-QSAR ANALYSIS STUDIES OF MMP-12 INHIBITORS

  2015cites this paper
• Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases

  2015cites this paper
• Multiple system atrophy : a translational approach Characterization of the insulin/IGF-1 signaling pathway

  2015cites this paper
• Concentrations of Matrix Metalloproteinases and their Tissue Inhibitors in the Cerebrospinal Fluid of Patients with Alzheimer's Disease

  2014cites this paper
• Endogenous and synthetic MMP inhibitors in CNS physiopathology.

  2014cites this paper
• The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in the Pathophysiology of Neurodegeneration: A Literature Study

  2013influential citation
• Design, synthesis and evaluation of 6-oxo-1, 6-dihydropyrimidine-2,5-dicarboxamide derivatives as MMP 13 inhibitors

  2013cites this paper
• QSAR Rationale of Matrix Metalloproteinase Inhibition Activity in a Class of Carboxylic Acid Based Compounds

  2013cites this paper
• An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines.

  2012cites this paper
• AN APOLIPOPROTEIN E4 FRAGMENT AFFECTS MMP9, TIMP1 AND CYTOKINE LEVELS IN BRAIN CELL LINES

  2012cites this paper
• A one-pot synthesis and biological activity of ageladine A and analogues.

  2011cites this paper
• Rôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer

  2010cites this paper
• Cellular and proteolytic studies of Alzheimer's disease amyloid beta peptide with microglia, stem cells and MMP9

  2010cites this paper
• The novel use of recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) to reverse cerebral amyloidosis and cognitive impairment in Alzheimer's disease mouse models: Insights from the investigation of Rheumatoid arthritis as a negative risk factor for Alzheimer's disease

  2010cites this paper
• Association of matrix metalloproteinases with MRI indices of brain ischemia and aging.

  2010cites this paper
• Increased alpha-synuclein aggregation following limited cleavage by certain matrix metalloproteinases.

  2009cites this paper
• Neuronal TIMP‐1 release accompanies astrocytic MMP‐9 secretion and enhances astrocyte proliferation induced by β‐amyloid 25–35 fragment

  2009cites this paper
• Metalloproteinase’s Activity and Oxidative Stress in Mild Cognitive Impairment and Alzheimer’s Disease

  2009cites this paper
• Extra binding region induced by non-zinc chelating inhibitors into the S1' subsite of matrix metalloproteinase 8 (MMP-8).

  2009cites this paper
• Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia

  2008cites this paper
• Stereoselectivity by enantiomeric inhibitors of matrix metalloproteinase-8: new insights from molecular dynamics simulations.

  2007cites this paper
• Analysis of two human gene clusters involved in innate immunity

  2007cites this paper
• Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

  2007cites this paper
• Identification of Protein Fold Topology Shared between Different Folds Inhibited by Natural Products

  2007cites this paper
• Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.

  2006cites this paper
• Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.

  2006cites this paper
• The expression and refolding of isotopically labeled recombinant Matrilysin for NMR studies.

  2006cites this paper
• Photoreceptor Degeneration : Photoreceptor Rescue and Role of Metalloproteases in Retinal Degeneration

  2005cites this paper
• rd1 Photoreceptor Degeneration: Photoreceptor Rescue and Role of Metalloproteases in Retinal Degeneration

  2005cites this paper
• QSAR-by-NMR: quantitative insights into structural determinants for binding affinity by analysis of 1H/15N chemical shift differences in MMP-3 ligands.

  2005cites this paper
• Design, modelling, synthesis and biological evaluation of peptidomimetic phosphinates as inhibitors of matrix metalloproteinases MMP-2 and MMP-8.

  2005cites this paper
• Synthesis, radiosynthesis, in vitro and preliminary in vivo evaluation of biphenyl carboxylic and hydroxamic matrix metalloproteinase (MMP) inhibitors as potential tumor imaging agents.

  2005cites this paper
• The TIMPs tango with MMPs and more in the central nervous system

  2004cites this paper
• Bioinformatic comparison of structures and homology-models of matrix metalloproteinases.

  2004cites this paper
• The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck

  2004cites this paper
• Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications.

  2004cites this paper
• A Ligand-Based Molecular Modeling Study on Some Matrix Metalloproteinase-1 Inhibitors Using Several 3D QSAR Techniques

  2004cites this paper
• Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy.

  2004cites this paper
• Matrix metalloprotease inhibitors: design from structure.

  2004cites this paper
• FLEXIBLE LIGAND DOCKING STUDIES OF MATRIX METALLOPROTEINASE INHIBITORS USING LAMARCKIAN GENETIC ALGORITHM

  2004cites this paper
• Recent advances in the design of matrix metalloprotease inhibitors.

  2004cites this paper
• Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes.

  2003cites this paper
• Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease.

  2003cites this paper
• Characterisation of a recombinant human cysteine dioxygenase

  2003cites this paper
• Parameterization and classification of the protein universe via geometric techniques.

  2003cites this paper
• β-Amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes

  2003cites this paper
• Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases.

  2003cites this paper
• Beta-propellers: associated functions and their role in human diseases.

  2003cites this paper
• The Degradation of Amyloid β as a Therapeutic Strategy in Alzheimer's Disease and Cerebrovascular Amyloidoses

  2002cites this paper
• Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's disease

  2002cites this paper
• Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease.

  2002cites this paper
• An Extracellular Matrix-Associated Zinc Metalloprotease Is Required for Dilauroyl Phosphatidylethanolamine Chemotactic Excitation in Myxococcus xanthus

  2002cites this paper
• Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.

  2002cites this paper
• Genetic polymorphisms and cerebrospinal £uid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer’s disease

  2002cites this paper
• Activated microglia in the human glaucomatous optic nerve head

  2001cites this paper
• Metalloproteinases in biology and pathology of the nervous system

  2001cites this paper
• Structural studies of matrix metalloproteinases

  2000cites this paper
• Unregulated inflammation shortens human functional longevity

  2000cites this paper
• Extracellular matrix degradation by metalloproteinases and central nervous system diseases

  1999cites this paper
• Affinity and selectivity of matrix metalloproteinase inhibitors: a chemometrical study from the perspective of ligands and proteins.

  1999cites this paper
• The potential use of MMP inhibitors to treat CNS diseases.

  1999cites this paper
• Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity.

  1999cites this paper
• Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.

  1999cites this paper
• Structure of recombinant mouse collagenase-3 (MMP-13).

  1999cites this paper
• Activated isoforms of MMP‐2 are induced in U87 human glioma cells in response to β‐amyloid peptide

  1999cites this paper
• Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral Ischemia

  1999cites this paper
• Regional and differential expression of gelatinases in rat brain after systemic kainic acid or bicuculline administration

  1998cites this paper
• Inflammatory Markers in Chronic Neurodegenerative Disorders with Emphasis on Alzheimer’s Disease

  1998cites this paper
• Induction of matrix metalloproteinase-2 in human immunodeficiency virus-1 glycoprotein 120 transgenic mouse brains.

  1998cites this paper
• Matrix metalloproteinases and diseases of the CNS.

  1998cites this paper
• Pathophysiology of the kallikrein-kinin system in mammalian nervous tissue.

  1998cites this paper
• Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states.

  1998cites this paper
• Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in HTLV-I-associated myelopathy.

  1998cites this paper
• Matrix metalloproteases: variations on a theme.

  1998cites this paper
• 1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile.

  1997cites this paper
• Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions

  1996cites this paper
• The helping hand of collagenase-3 (MMP-13): 2.7 A crystal structure of its C-terminal haemopexin-like domain.

  1996cites this paper
• Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons.

  1996cites this paper
• The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases.

  1995cites this paper